APRE — Aprea Therapeutics, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2019-10-03.
Performance
Technicals
Others in Healthcare
Measured signals that fired on APRE
| date | signal | measured base rate |
|---|---|---|
| 2026-03-26 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-06-16 | HENNEMAN JOHN B III Director | Grant or award | 3.1K | 0.00 | 0 |
| 2026-06-16 | Duey Marc Director | Grant or award | 3.1K | 0.00 | 0 |
| 2026-06-16 | Pamukcu Rifat Director | Grant or award | 3.1K | 0.00 | 0 |
| 2026-06-16 | Seizinger Bernd R. Director | Grant or award | 3.1K | 0.00 | 0 |
| 2026-06-16 | Peters Richard Director | Grant or award | 3.1K | 0.00 | 0 |
| 2026-06-16 | Gruia Gabriela Director | Grant or award | 3.1K | 0.00 | 0 |
| 2026-06-16 | Grissinger Michael Director | Grant or award | 3.1K | 0.00 | 0 |
| 2026-06-16 | BIZZARI JEAN-PIERRE Director | Grant or award | 3.1K | 0.00 | 0 |
| 2026-03-12 | Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr | Grant or award | 10.1K | 0.00 | 0 |
| 2026-03-12 | Gilad Oren President/CEO | Grant or award | 20.2K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| AIGH Capital Management LLC | 774.8K | 1.0M |
| Vestal Point Capital, LP | 267.0K | 350.0K |
| SPHERA FUNDS MANAGEMENT LTD. | 206.0K | 270.0K |
| Nantahala Capital Management, LLC | 157.0K | 205.8K |
| GEODE CAPITAL MANAGEMENT, LLC | 90.9K | 119.1K |
| Scientech Research LLC | 46.0K | 60.3K |
| BNP PARIBAS FINANCIAL MARKETS | 30.4K | 39.8K |
| VANGUARD FIDUCIARY TRUST CO | 29.3K | 38.5K |
| RENAISSANCE TECHNOLOGIES LLC | 19.1K | 25.1K |
| MORGAN STANLEY | 17.0K | 22.3K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| SCHEDULE 13G/A | 2026-08-13 | — | on EDGAR ↗ |
| 10-Q | 2026-08-12 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-08-12 | 2026-08-12 | on EDGAR ↗ |
| 8-K | 2026-07-23 | 2026-07-23 | on EDGAR ↗ |
| 4 | 2026-06-17 | 2026-06-16 | on EDGAR ↗ |
| 4 | 2026-06-17 | 2026-06-16 | on EDGAR ↗ |
| 4 | 2026-06-17 | 2026-06-16 | on EDGAR ↗ |
| 4 | 2026-06-17 | 2026-06-16 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Aprea Therapeutics, Inc. (APRE) filed form 8-K · 2026-08-12 · SEC EDGAR
- Aprea Therapeutics GAAP EPS of -$0.07 beats by $0.16 · 2026-08-12
Ask the AI about APRE
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →